Dimerix chief Nina Webster on the potential multi-billion dollar market for DXB’s FSGS kidney treatment

Special Report: Along with its near-term FSGS opportunity, the company is still fully committed to developing its DMX-200 treatment for … Read More

The post Dimerix chief Nina Webster on the potential multi-billion dollar market for DXB’s FSGS kidney treatment appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *